The use of totally implantable central venous access ports for the treatment of multidrug-resistant tuberculosis (MDR-TB) at the programmatic level. Prospective cohort study

Conclusions: The use TICVAP for the patients on new MDR-TB regimens with long term IV infusions demonstrates good safety profile and high level of patients and HCP acceptability.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Skrahin, A., Pechinski, D., Makouski, M., Hurevich, H., Sinha, A., Aliushin, S., Grankov, V., Skrahina, A. Tags: Tuberculosis Source Type: research